Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200012 | 0.88 | NAAA (0.52) | NAAAEPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL2085132 | 0.88 | HPGD (0.46) | PTGS2 | |
| SCHEMBL2083239 | 0.88 | HPGD (0.46) | PTGS2 | |
| SCHEMBL2083468 | 0.88 | HPGD (0.46) | PTGS2 | |
| SCHEMBL4137357 | 0.88 | NAAA (0.58) | NAAAEPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL4228293 | 0.87 | EGFR (0.49) | ALOX15ALDH1A1NPC1RAB9APTGS2 | |
| SCHEMBL2083408 | 0.87 | EGFR (0.49) | ALOX15ALDH1A1NPC1RAB9APTGS2 | |
| SCHEMBL2083411 | 0.87 | EGFR (0.49) | ALOX15ALDH1A1NPC1RAB9APTGS2 | |
| SCHEMBL5364431 | 0.87 | LTB4R2 (0.45) | NAAAALOX15PTGS2 | |
| SCHEMBL2083094 | 0.86 | HPGD (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | disclosed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | NAAA 1943/4885ALOX15 143/4885EPHX1 1121/4885 |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | PPARG, PPARA, PPARD | NAAA 1781/4885ALOX15 189/4885EPHX1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.